Cargando…

Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells

Effective new therapies are urgently needed for the treatment of multiple myeloma (MM), an incurable hematological malignancy. In this study, we evaluated the effects of piperlongumine on MM cell proliferation both in vivo and in vitro. Piperlongumine inhibited the proliferation of MM cells by induc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Yao, Sun, Yueyue, Shi, Min, Xia, Dandan, Zhao, Kai, Zeng, Lingyu, Yao, Ruosi, Zhang, Ying, Li, Zhenyu, Niu, Mingshan, Xu, Kailin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341994/ https://www.ncbi.nlm.nih.gov/pubmed/27634873 http://dx.doi.org/10.18632/oncotarget.11988

Ejemplares similares

The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma
por: Sun, Xiaoyang, et al.
Publicado: (2019)

Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells
por: Yao, Ruosi, et al.
Publicado: (2018)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma
por: Chen, Runzhe, et al.
Publicado: (2017)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Solamargine induces autophagy‐mediated apoptosis and enhances bortezomib activity in multiple myeloma
por: Han, Qiaoyan, et al.
Publicado: (2022)

Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer
por: Chen, Di, et al.
Publicado: (2019)

Identification of a Novel c-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma
por: Yao, Ruosi, et al.
Publicado: (2020)

Preformulation Studies on Piperlongumine
por: Aodah, Alhassan, et al.
Publicado: (2016)

Survivin Promotes Piperlongumine Resistance in Ovarian Cancer
por: Nan, Xing-Wei, et al.
Publicado: (2019)

High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia
por: Niu, Mingshan, et al.
Publicado: (2019)

Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability
por: Yao, Ruosi, et al.
Publicado: (2022)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Anti-Proliferative Activity of HPOB against Multiple Myeloma Cells via p21 Transcriptional Activation
por: Liu, Linlin, et al.
Publicado: (2018)

TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy
por: Chen, Jing, et al.
Publicado: (2023)

Attenuation of STAT3 Signaling Cascade by Daidzin Can Enhance the Apoptotic Potential of Bortezomib against Multiple Myeloma
por: Yang, Min Hee, et al.
Publicado: (2019)

Metabolic profile and safety of piperlongumine
por: de Lima Moreira, Fernanda, et al.
Publicado: (2016)

NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2022)

YL064 directly inhibits STAT3 activity to induce apoptosis of multiple myeloma cells
por: Wang, Yingying, et al.
Publicado: (2018)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
por: Zhou, Pan, et al.
Publicado: (2022)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Tumor lysis syndrome in multiple myeloma treated with bortezomib
por: Dhanraj, K. M., et al.
Publicado: (2014)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2017)

A feline case of multiple myeloma treated with bortezomib
por: Tani, Hiroyuki, et al.
Publicado: (2022)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
por: Han, Joseph, et al.
Publicado: (2023)

Piperlongumine Induces Apoptosis and Synergizes with Cisplatin or Paclitaxel in Human Ovarian Cancer Cells
por: Gong, Li-Hua, et al.
Publicado: (2014)

Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China
por: Yao, Rongxin, et al.
Publicado: (2019)

PSMB7 Is a Key Gene Involved in the Development of Multiple Myeloma and Resistance to Bortezomib
por: Wu, Dong, et al.
Publicado: (2021)

Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
por: Ashrafi, Farzaneh, et al.
Publicado: (2020)

Identification of Piperlongumine as Potent Inhibitor of Necroptosis
por: He, Xiaoyan, et al.
Publicado: (2023)

Identification of Potential Prognostic Biomarker for Predicting Survival in Multiple Myeloma Using Bioinformatics Analysis and Experiments
por: Zhou, Jian, et al.
Publicado: (2021)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib
por: Wu, Cuicui
Publicado: (2022)

Piperlongumine Is an NLRP3 Inhibitor With Anti-inflammatory Activity
por: Shi, Jie, et al.
Publicado: (2022)

PB2079: LACTATE DECREASES BORTEZOMIB SENSITIVITY AND PREDICTS POOR CLINICAL OUTCOMES OF MULTIPLE MYELOMA
por: MA, Naya, et al.
Publicado: (2023)

Piperlongumin Improves Survival in the Mouse Model of Sepsis: Effect on Coagulation Factors and Lung Inflammation
por: Fang, Zhendong, et al.
Publicado: (2022)

Piperlongumine Analogs Promote A549 Cell Apoptosis through Enhancing ROS Generation
por: Sun, Ai-Ling, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0b3m83l9fmnks7ajb9t3ro606b